RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational Highlights

– Achieved record quarterly revenues of $21.5 million for Q2/2021, 4.5% increase from Q1/2021 despite challenging market conditions; Cash balance 1  of approximately $71.5 million as of June 30, 2021 – Record Talicia® quarterly prescription volume up more than 10%; Movantik® quarterly new prescriptions up 5.6%; Talicia and Movantik coverage expanded to 8 and 9 out of 10 commercially insured Americans, […]

thaipr.net

30 ส.ค. 64
1 2,802 2,803 2,804 2,805 2,806 3,312